指南与共识系统性红斑狼疮

2026年英国风湿病学会系统性红斑狼疮管理指南

The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.
指南 / 共识 · Rheumatology (Oxford) · 2026-01-01

该指南由英国风湿病学会工作组制定,覆盖儿童、青少年及成人系统性红斑狼疮(SLE)的全生命周期管理。工作组系统综述文献并形成102条推荐,涵盖评估、诊断、监测、非药物与药物治疗、狼疮肾炎及皮肤狼疮等器官特异性治疗,并提出研究与审计建议。

要点

  • 指南涵盖SLE从儿童到成人的全生命周期管理,强调赋能患者、抑制疾病活动、预防器官损伤。
  • 共形成102条推荐,每条附推荐强度和同意评分,涉及诊断、监测、治疗及器官特异性管理。
  • 提供研究与审计建议,以支持公平获取医疗并改善SLE健康结局。

核心结论

  • SLE管理应赋能患者自我管理、抑制系统性疾病活动并预防器官损伤。

研究设计与样本

  • 英国风湿病学会指南工作组制定,成员包括儿科与成人SLE专家及患者代表。
  • 工作组回顾已发表指南、开展系统文献综述并利用英国专科狼疮中心经验形成推荐。

主要发现

  • 共形成102条推荐,每条附推荐强度和同意评分。
  • 推荐涵盖评估、诊断、监测、一般管理方法、非药物与药物治疗、狼疮肾炎及皮肤狼疮等器官特异性治疗。
  • 推荐还涉及英国医疗体系下的照护提供,并提供研究与审计建议。

关键数值与推荐

  • 共102条推荐,附对应推荐强度和同意评分。

临床怎么用

  • 临床可依据102条推荐进行SLE的评估、诊断、监测及器官特异性治疗决策。
  • 应结合英国医疗体系背景提供照护,并参考研究与审计建议改善公平获取与结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic lupus erythematosus (SLE) is a lifelong autoimmune condition with multi-system involvement that is associated with morbidity, mortality, and poor quality of life. The key aim of management should be to empower individuals with SLE to manage their condition, suppressing systemic disease activity, and preventing organ damage. This guideline builds on and expands the recommendations developed for the first guideline published in 2017 for adults living with SLE. This comprehensive life-course guideline was developed according to the British Society for Rheumatology Guidelines Protocol by a Guideline Working Group (GWG) comprising healthcare professionals with expertise in paediatric and adult SLE, and people with lived experience. The GWG reviewed published guidelines, undertook a systematic literature review and utilised expertise from specialist lupus centres across the UK and patient representatives to formulate a list of 102 recommendations with corresponding strength of recommendations and agreement scores. These recommendations encompass advances in the assessment, diagnosis, monitoring, general approaches to management, non-pharmacological and pharmacological management of SLE, organ-specific treatment including lupus nephritis and cutaneous lupus erythematosus, as well as the delivery of care in the context of the UK healthcare system. Furthermore, we have provided research and audit recommendations to support equitable access to care and improve health outcomes in SLE.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Smith EMD, Lythgoe H, et al. The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus. Rheumatology (Oxford). 2026. PMID: 42336388. doi:10.1093/rheumatology/keag223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。